Research Grade Rosmantuzumab (DHJ51101)

Catalog No.

DHJ51101

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Humanized

Isotype

IgG1-kappa

Clonality

Monoclonal

Target

RSPO3, hPWTSR, hRspo3, PWTSR, R-spondin-3, Thrombospondin type-1 domain-containing protein 2, Protein with TSP type-1 repeat, Roof plate-specific spondin-3, THSD2

Concentration

1.72 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q9BXY4

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

OMP-131R10, CAS: 1684393-04-1

Clone ID

Rosmantuzumab

Multi‑layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/β‑catenin signaling activation (Review), PMID: 29786110

Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review), PMID: 29048660

Molecular genetics and targeted therapy of WNT-related human diseases (Review), PMID: 28731148

Targeting RSPO3-LGR4 Signaling for Leukemia Stem Cell Eradication in Acute Myeloid Leukemia, PMID: 32559496

Zheng, H., Liu, J., Cheng, Q., Zhang, Q., Zhang, Y., Jiang, L., Huang, Y., Li, W., Zhao, Y., Chen, G., et al. (2024). Targeted activation of ferroptosis in colorectal cancer via LGR4 targeting overcomes acquired drug resistance. Nat Cancer 5, 572-589. PMID: 38291304

Document Download

Research Grade Rosmantuzumab.pdf